Is At-Home Ketamine Therapy Safe?

The Short Answer

At-home ketamine therapy — in which patients take prescribed ketamine (typically sublingual troches or lozenges) in their homes rather than in a clinical setting — has become an increasingly common treatment model. Its safety depends heavily on the quality of clinical oversight, patient selection, dosing protocols, and the presence of appropriate safeguards. When conducted under proper medical supervision with established safety protocols, at-home ketamine can be a reasonable option for appropriate patients. When conducted without adequate oversight, it carries meaningful risks.

How At-Home Ketamine Works

The Typical Model

At-home ketamine therapy generally follows this structure:

1. Initial evaluation — A clinician (often through a telehealth platform) conducts a psychiatric and medical assessment to determine candidacy
2. Prescription — If appropriate, the clinician prescribes a compounded ketamine formulation (most commonly sublingual troches) from a partnering compounding pharmacy
3. Medication delivery — The medication is shipped directly to the patient's home
4. Self-administration — The patient takes the medication at home according to prescribed instructions, typically once to several times per week
5. Follow-up — The prescribing clinician conducts periodic follow-up appointments (usually via telehealth) to assess response and adjust the treatment plan

Formulations Used

The most common formulations for at-home use are sublingual troches and lozenges, which deliver ketamine through the oral mucosa. Compounded nasal sprays and oral tablets are also prescribed by some providers. These formulations have lower bioavailability (25-35% for sublingual, 17-24% for oral) compared to IV or IM administration, resulting in a generally milder and more manageable psychoactive experience at typical at-home doses.

Arguments for Safety

Lower Doses and Bioavailability

At-home protocols typically use doses and formulations that produce milder effects than in-clinic IV or IM treatments. The lower bioavailability of sublingual administration means that the peak plasma concentrations are generally lower, reducing the intensity of dissociation and cardiovascular effects. Many at-home patients describe the experience as a mild, dreamlike state rather than the more profound dissociation that can occur with IV infusion.

Patient Selection

Responsible at-home ketamine programs screen patients carefully, excluding those with:

• Active psychosis or schizophrenia
• Uncontrolled hypertension or significant cardiovascular disease
• Active substance use disorders (particularly involving ketamine or similar substances)
• History of severe adverse reactions to ketamine
• Inability to arrange for a treatment sitter
• Acute suicidal ideation requiring a higher level of care

This screening process, when conducted thoroughly, ensures that at-home treatment is limited to patients who are medically and psychologically appropriate for a lower level of clinical oversight.

Established Track Record

Thousands of patients have received at-home ketamine therapy through various telehealth platforms and prescribers over the past several years. While formal safety data from these programs are limited, the overall rate of serious adverse events reported to regulatory agencies has been relatively low. The most common adverse effects — nausea, dizziness, and mild dissociation — are consistent with those seen in clinical settings.

Arguments for Caution

Reduced Medical Oversight

The most significant safety concern with at-home ketamine is the absence of real-time medical monitoring. In a clinical setting, blood pressure, heart rate, and oxygen saturation are continuously monitored, and trained staff are immediately available to manage any adverse event. At home, this safety infrastructure does not exist.

Specific risks of reduced oversight include:

• Undetected blood pressure elevation that could be clinically significant in vulnerable patients
• Unmonitored falls or injuries if the patient attempts to move while dissociated
• Delayed recognition of adverse psychological reactions
• Absence of emergency intervention capability for rare but serious events

Risk of Misuse

At-home access to ketamine creates a risk of misuse — taking doses higher than prescribed, using more frequently than directed, or sharing the medication with others. While this risk is present with many prescribed medications, ketamine's psychoactive properties and Schedule III classification make it a particular concern. Responsible programs implement safeguards including limited quantities per shipment, regular check-ins, and urine drug screening in some cases.

Inadequate Screening

The quality of initial screening varies significantly across at-home ketamine providers. Some programs conduct thorough evaluations with detailed psychiatric and medical assessments, while others offer brief, cursory consultations. Inadequate screening increases the risk that patients with contraindications — such as uncontrolled hypertension, psychotic disorders, or active substance abuse — will receive ketamine inappropriately.

Regulatory Concerns

Federal and state regulatory agencies have expressed concerns about at-home ketamine prescribing, particularly through telehealth. The FDA issued a public safety alert in 2023 regarding compounded ketamine products used at home, citing reports of adverse events and emphasizing the importance of medical supervision. Several states have enacted or proposed regulations specifically addressing the prescribing of controlled substances via telehealth for at-home use.

Safety Protocols for At-Home Treatment

The Treatment Sitter

Most responsible at-home ketamine protocols require the presence of a treatment sitter — a sober, responsible adult who remains with the patient throughout the ketamine session and for at least one hour afterward. The sitter's responsibilities include:

• Ensuring the patient remains safe during the dissociative experience
• Preventing the patient from driving, cooking, or engaging in potentially dangerous activities
• Contacting the prescriber or emergency services if any concerns arise
• Providing reassurance if the patient becomes anxious or disoriented

Environmental Preparation

Patients should prepare their home environment for treatment:

• Choose a quiet, comfortable, and private room
• Remove potential hazards (sharp objects, tripping risks)
• Have a phone accessible for emergencies
• Prepare comfortable seating or a reclining position
• Minimize external disturbances (turn off phone notifications, inform household members)

Dosing Adherence

Strict adherence to the prescribed dose and frequency is essential. Patients should:

• Take only the exact dose prescribed
• Follow the prescribed schedule without self-adjusting
• Not combine ketamine with alcohol, sedatives, or other substances unless specifically approved by the prescriber
• Store medication securely, out of reach of children or others in the household

Monitoring and Follow-Up

Quality at-home programs include:

• Regular follow-up appointments (at least monthly, often biweekly initially)
• Standardized mood and symptom assessments at each visit
• Home blood pressure monitoring before and after sessions (recommended by some providers)
• Clear instructions for when to contact the prescriber or seek emergency care
• Mechanisms for the prescriber to discontinue treatment if concerns arise

Comparing Safety: At-Home vs. In-Clinic

Who Should and Should Not Consider At-Home Treatment

Potentially Appropriate Candidates

• Patients who have previously tolerated ketamine in a clinical setting without significant adverse effects
• Patients with stable vital signs and no uncontrolled cardiovascular conditions
• Patients who can reliably arrange for a treatment sitter
• Patients who live far from in-clinic ketamine providers — see at-home ketamine companies for an overview of available services
• Patients for whom cost is a significant barrier to in-clinic treatment
• Patients with a demonstrated ability to adhere to prescribed protocols

Patients Who Should Avoid At-Home Treatment

• Patients who have never received ketamine before (initial treatment in a clinical setting is recommended)
• Patients with uncontrolled hypertension or cardiovascular disease
• Patients with active psychotic symptoms or a psychotic disorder
• Patients with active substance use disorders
• Patients who cannot arrange for a treatment sitter
• Patients with acute suicidal ideation requiring a higher level of care
• Patients with a history of adverse reactions to ketamine

Note: This article is for educational purposes only and does not constitute medical advice. At-home ketamine therapy should only be initiated and supervised by a qualified healthcare provider, and patients should carefully follow all prescribed safety protocols.

References

• StatPearls: Ketamine — Clinical reference covering ketamine safety profile, monitoring requirements, and adverse effect management
• FDA: Drug Information — FDA resource on drug safety, including compounded ketamine safety communications
• MedlinePlus: Ketamine Injection — National Library of Medicine information on ketamine precautions and side effects
• Ketamine Pharmacology: An Update — NIH review of ketamine pharmacology including bioavailability and safety considerations by route